Applicazioni della proteomica in ambito ginecologico-ostetrico

Translated title of the contribution: Proteomic applications in gynecologyobstetrics

F. De Seta, R. Banco, S. Guaschino, D. De Santo, A. Turrisi, C. Piva

Research output: Contribution to journalArticle

Abstract

Proteomics has recently emerged as a powerful approach both for discovering biomarkers as well as for understanding the physiopathology of unclear gynecological-obstetrical disorders. Currently, several biological fluids and fetal tissues were successfully tested, including maternal plasma, amniotic fluid, cervical-vaginal fluid, urine, saliva, placental trophoblast, amnio-chorionic membranes and cord blood. The potential of proteomics on the polycystic ovary syndrome (PCOS) involves biomarkers discovery for a more accurate diagnosis of the syndrome and identification, within the patients with PCOS, those who respond more easily to treatment and those who will be at increased risk for future metabolic complications. The proteomic approach applied to patients with endometriosis would allow not only a non-invasive early diagnosis, but also a staging of the disease and a prediction of infertility risk. Proteomics also involves oncological field, in order to discover biomarkers that allow early diagnosis and prognosis of female genital malignancies. In addition to this, proteomics could be used to understand and predict obstetrical complications such as recurrent spontaneous abortion, preterm birth and preeclampsia. However, further studies are needed on a larger cohort of patients to introduce these biomarkers in clinical practice.

Original languageItalian
Pages (from-to)39-46
Number of pages8
JournalMinerva Ginecologica
Volume63
Issue number1
Publication statusPublished - Feb 2011

Fingerprint

Proteomics
Biomarkers
Polycystic Ovary Syndrome
Early Diagnosis
Habitual Abortion
Premature Birth
Trophoblasts
Spontaneous Abortion
Endometriosis
Amniotic Fluid
Pre-Eclampsia
Fetal Blood
Saliva
Infertility
Fetus
Mothers
Urine
Membranes
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

De Seta, F., Banco, R., Guaschino, S., De Santo, D., Turrisi, A., & Piva, C. (2011). Applicazioni della proteomica in ambito ginecologico-ostetrico. Minerva Ginecologica, 63(1), 39-46.

Applicazioni della proteomica in ambito ginecologico-ostetrico. / De Seta, F.; Banco, R.; Guaschino, S.; De Santo, D.; Turrisi, A.; Piva, C.

In: Minerva Ginecologica, Vol. 63, No. 1, 02.2011, p. 39-46.

Research output: Contribution to journalArticle

De Seta, F, Banco, R, Guaschino, S, De Santo, D, Turrisi, A & Piva, C 2011, 'Applicazioni della proteomica in ambito ginecologico-ostetrico', Minerva Ginecologica, vol. 63, no. 1, pp. 39-46.
De Seta F, Banco R, Guaschino S, De Santo D, Turrisi A, Piva C. Applicazioni della proteomica in ambito ginecologico-ostetrico. Minerva Ginecologica. 2011 Feb;63(1):39-46.
De Seta, F. ; Banco, R. ; Guaschino, S. ; De Santo, D. ; Turrisi, A. ; Piva, C. / Applicazioni della proteomica in ambito ginecologico-ostetrico. In: Minerva Ginecologica. 2011 ; Vol. 63, No. 1. pp. 39-46.
@article{8317149bde2b45d2bf9769347875d949,
title = "Applicazioni della proteomica in ambito ginecologico-ostetrico",
abstract = "Proteomics has recently emerged as a powerful approach both for discovering biomarkers as well as for understanding the physiopathology of unclear gynecological-obstetrical disorders. Currently, several biological fluids and fetal tissues were successfully tested, including maternal plasma, amniotic fluid, cervical-vaginal fluid, urine, saliva, placental trophoblast, amnio-chorionic membranes and cord blood. The potential of proteomics on the polycystic ovary syndrome (PCOS) involves biomarkers discovery for a more accurate diagnosis of the syndrome and identification, within the patients with PCOS, those who respond more easily to treatment and those who will be at increased risk for future metabolic complications. The proteomic approach applied to patients with endometriosis would allow not only a non-invasive early diagnosis, but also a staging of the disease and a prediction of infertility risk. Proteomics also involves oncological field, in order to discover biomarkers that allow early diagnosis and prognosis of female genital malignancies. In addition to this, proteomics could be used to understand and predict obstetrical complications such as recurrent spontaneous abortion, preterm birth and preeclampsia. However, further studies are needed on a larger cohort of patients to introduce these biomarkers in clinical practice.",
keywords = "Endometriosis, Polycystic ovary syndrome, Preeclampsia, Premature birth, Proteomics",
author = "{De Seta}, F. and R. Banco and S. Guaschino and {De Santo}, D. and A. Turrisi and C. Piva",
year = "2011",
month = "2",
language = "Italian",
volume = "63",
pages = "39--46",
journal = "Minerva Ginecologica",
issn = "0026-4784",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Applicazioni della proteomica in ambito ginecologico-ostetrico

AU - De Seta, F.

AU - Banco, R.

AU - Guaschino, S.

AU - De Santo, D.

AU - Turrisi, A.

AU - Piva, C.

PY - 2011/2

Y1 - 2011/2

N2 - Proteomics has recently emerged as a powerful approach both for discovering biomarkers as well as for understanding the physiopathology of unclear gynecological-obstetrical disorders. Currently, several biological fluids and fetal tissues were successfully tested, including maternal plasma, amniotic fluid, cervical-vaginal fluid, urine, saliva, placental trophoblast, amnio-chorionic membranes and cord blood. The potential of proteomics on the polycystic ovary syndrome (PCOS) involves biomarkers discovery for a more accurate diagnosis of the syndrome and identification, within the patients with PCOS, those who respond more easily to treatment and those who will be at increased risk for future metabolic complications. The proteomic approach applied to patients with endometriosis would allow not only a non-invasive early diagnosis, but also a staging of the disease and a prediction of infertility risk. Proteomics also involves oncological field, in order to discover biomarkers that allow early diagnosis and prognosis of female genital malignancies. In addition to this, proteomics could be used to understand and predict obstetrical complications such as recurrent spontaneous abortion, preterm birth and preeclampsia. However, further studies are needed on a larger cohort of patients to introduce these biomarkers in clinical practice.

AB - Proteomics has recently emerged as a powerful approach both for discovering biomarkers as well as for understanding the physiopathology of unclear gynecological-obstetrical disorders. Currently, several biological fluids and fetal tissues were successfully tested, including maternal plasma, amniotic fluid, cervical-vaginal fluid, urine, saliva, placental trophoblast, amnio-chorionic membranes and cord blood. The potential of proteomics on the polycystic ovary syndrome (PCOS) involves biomarkers discovery for a more accurate diagnosis of the syndrome and identification, within the patients with PCOS, those who respond more easily to treatment and those who will be at increased risk for future metabolic complications. The proteomic approach applied to patients with endometriosis would allow not only a non-invasive early diagnosis, but also a staging of the disease and a prediction of infertility risk. Proteomics also involves oncological field, in order to discover biomarkers that allow early diagnosis and prognosis of female genital malignancies. In addition to this, proteomics could be used to understand and predict obstetrical complications such as recurrent spontaneous abortion, preterm birth and preeclampsia. However, further studies are needed on a larger cohort of patients to introduce these biomarkers in clinical practice.

KW - Endometriosis

KW - Polycystic ovary syndrome

KW - Preeclampsia

KW - Premature birth

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=79955772303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955772303&partnerID=8YFLogxK

M3 - Articolo

C2 - 21311419

AN - SCOPUS:79955772303

VL - 63

SP - 39

EP - 46

JO - Minerva Ginecologica

JF - Minerva Ginecologica

SN - 0026-4784

IS - 1

ER -